

**SAMPLE FLOW CYTOMETRY REPORT**

**DIAGNOSIS:**

**ABC HOSPITAL #B05-XXXX**

Peripheral blood:

1. Abnormal CD4+ T cell population identified (see comment).
2. No abnormal B cell population identified.


**COMMENT**


An abnormal T cell population (colored black in histograms below), which represents ~16% of the total leukocytes, is identified. This population expresses intermediate CD2, CD3, CD4, CD5, and  $\alpha$ - $\beta$  T cell receptor, with low-intermediate CD8 and CD56, and aberrant loss of CD7. In addition, the abnormal T cells express intermediate CD52, without significant CD25 or CD30. These findings would be consistent with involvement by a T cell neoplasm in the appropriate clinical and morphologic context; if clinically indicated, the specimen can be forwarded for molecular studies to confirm a clonal T cell population. No evidence of B cell non-Hodgkin lymphoma, nor of an NK cell proliferation, is identified by flow cytometry. Correlation of these findings with the morphology of the fresh peripheral blood smear is recommended.

**RECEIVED FOR THE FOLLOWING:**

Flow cytometry to rule out lymphoma.

**RESULTS:**





Immunophenotyping by flow cytometry after lysis of the erythroid cells reveals that the white blood cells consist of 51% lymphocytes, 6.3% monocytes, and 39% granulocytes. The lymphocytes consist of 16% B cells (CD19+), 65% T cells (CD3+), and 16% NK cells (CD3-, CD7+).

**ANTIBODIES USED:** CD45, CD19, kappa, lambda, CD20, CD38, CD56, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD34, CD25, CD30, CD52, TCR- $\alpha/\beta$ , TCR- $\gamma-\delta$

\*\*\***ELECTRONICALLY SIGNED**\*\*\*

**Steven J. Kussick, M.D., Ph.D.**  
**Hematopathologist**

*In compliance with CMS regulations, the pathologist's signature on this report indicates that the case has been personally reviewed, and the diagnosis made or confirmed by the Pathologist.*

NOTE: Some of the tests reported here may have been developed and performance characteristics determined by PhenoPath Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. PhenoPath Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.